Variants in mitochondrial amidoxime reducing component 1 and hydroxysteroid 17-beta dehydrogenase 13 reduce severity of nonalcoholic fatty liver disease in children and suppress fibrotic pathways through distinct mechanisms

EU-PNAFLD Investigators, Christian A Hudert, Leon A Adams, Anna Alisi, Quentin M Anstee, Annalisa Crudele, Laura G Draijer, Samuel Furse, Jan G Hengstler, Benjamin Jenkins, Kylie Karnebeek, Deirdre A Kelly, Bart G Koot, Albert Koulman, David Meierhofer, Phillip E Melton, Trevor A Mori, Stuart G Snowden, Indra van Mourik, Anita VreugdenhilSusanna Wiegand, Jake P Mann

Research output: Contribution to journalArticlepeer-review

18 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Variants in mitochondrial amidoxime reducing component 1 and hydroxysteroid 17-beta dehydrogenase 13 reduce severity of nonalcoholic fatty liver disease in children and suppress fibrotic pathways through distinct mechanisms'. Together they form a unique fingerprint.

Biochemistry, Genetics and Molecular Biology